CoChat
Sign Up
Cited by 78Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Therapy for Metastatic Colorectal Cancer

Open access
Goldberg, Richard M.·2006·The Oncologist
DOI 10.1634/theoncologist.11-9-981
Open this paper in CoChat — free accountOpen PDF

Abstract

Learning Objectives: After completing this course, the reader will be able to: Compare toxicity profiles among combination chemotherapy programs for colorectal cancer.Identify median survival times for chemotherapy programs for colorectal cancer.Discuss the new Intergroup trial schema and the rationale behind the study. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Overview

Integrity signals

Registry

Crossref · 10.1634/theoncologist.11-9-981

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Kelly, 2005, Systemic therapy for metastatic colorectal cancer: current options, current evidence, J Clin Oncol, 23, 4553, 10.1200/JCO.2005.17.749 · DOI
  2. Grothey, 2004, Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment, J Clin Oncol, 22, 1209, 10.1200/JCO.2004.11.037 · DOI · Paper page
  3. Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 · DOI · Paper page
  4. de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study, J Clin Oncol, 15, 808, 10.1200/JCO.1997.15.2.808 · DOI
  5. Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI
  6. Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017 · DOI
  7. Kabbinavar, 2005, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, J Clin Oncol, 23, 3706, 10.1200/JCO.2005.00.232 · DOI · Paper page
  8. Maughan, Fluorouracil (FU), oxaliplatin (Ox), CPT-11 (irinotecan, Ir), use and sequencing, in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) trial. 2005 Gastrointestinal Cancers Symposium: 165a
  9. Seymour, Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). 2005 ASCO Annual Meeting: 3518a
  10. D'Andre, 2005, 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a North Central Cancer Treatment Group study, Clin Colorectal Cancer, 4, 325, 10.3816/CCC.2005.n.005 · DOI
  11. De Gramont, OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer, J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.), 22, 3525
  12. Tournigand, 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer, J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.), 22, 3565
  13. de Gramont, 1997, [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers, Rev Med Interne, 18, 372s, 10.1016/S0248-8663(97)83768-X · DOI
  14. Kohne, 2003, Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952, J Clin Oncol, 21, 3721, 10.1200/JCO.2003.11.122 · DOI
  15. Hoff, 2001, The evolution of fluoropyrimidine therapy: from intravenous to oral, The Oncologist, 6, 3, 10.1634/theoncologist.6-suppl_4-3 · DOI
  16. Van Cutsem, 2001, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with meta-static colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097 · DOI
  17. Goldberg, 2002, Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program, J Clin Oncol, 20, 4591, 10.1200/JCO.2002.03.039 · DOI
  18. Delaunoit, 2004, Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741, Cancer, 101, 2170, 10.1002/cncr.20594 · DOI
  19. Schmoll, 2006, Update on capecitabine in colorectal cancer, The Oncologist, 11, 1003, 10.1634/theoncologist.11-9-1003 · DOI
  20. Reddy, 2005, Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer, Clin Colorectal Cancer, 4, 296, 10.1016/S1533-0028(11)70130-X · DOI
  21. de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
  22. Colucci, 2005, Phase III randomized trial of FOL-FIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale, J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113 · DOI
  23. Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 · DOI · Paper page
  24. Hurwitz, 2004, Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer, Clin Colorectal Cancer, 4, S62, 10.3816/CCC.2004.s.010 · DOI
  25. Fernando, 2004, Targeted therapy of colorectal cancer: clinical experience with bevacizumab, The Oncologist, 9, 11, 10.1634/theoncologist.9-suppl_1-11 · DOI
  26. Tyagi, 2005, Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial, Clin Colorectal Cancer, 5, 24, 10.1016/S1533-0028(11)70162-1 · DOI
  27. Giantonio, 2005, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200, Proc Am Soc Clin Oncol, 24, 2a, 10.1200/jco.2005.23.16_suppl.2 · DOI
  28. Erlichman, 2004, New treatment options for colorectal cancer, N Engl J Med, 351, 391, 10.1056/NEJMe048151 · DOI
  29. Saltz, Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
  30. Saltz, 2005, Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer, Proc Am Soc Clin Oncol, 24, 3508a, 10.1200/jco.2005.23.16_suppl.3508 · DOI
  31. Hecht, 2005, A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adeno-carcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1), Proc Am Soc Clin Oncol, 24, 3a, 10.1200/jco.2005.23.16_suppl.lba3 · DOI
  32. Tabernero, An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results, J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.), 22, 3512a
  33. Fisher, A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.), 22, 3514a
  34. Zampino, First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.), 22, 3659a

Cited by

Sorted by citations

Metadata

Authors
Goldberg, R. M.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Goldberg, Richard M.
ORCID
Goldberg, Richard M.
Venue
The Oncologist
Publisher
Oxford University Press (OUP)
Published
2006-10-01
Volume
11
Issue
9
Pages
981-987
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
DOI
10.1634/theoncologist.11-9-981
OpenAlex
W2152740887
Cited by
78
References
2
Citations by year
2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 5 · 2012: 3
FWCI
0.68
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • The Oncologist (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
metastatic colorectal cancer, combination chemotherapy, oxaliplatin, anti-VEGF antibody, anti-EGFR monoclonal antibody, biologic therapy, chemotherapy sequencing, overall survival, curative resection
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Neoplasm Metastasis, Colorectal Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review